Minimal residual disease (MRD) continues to be a central focus at the AACR meeting. The small numbers of cancer cells that remain in the body after treatment helps gauge the effectiveness of a ...
MRD refers to cancer cells remaining post-treatment, undetectable by standard imaging, indicating potential recurrence risk. MRD testing methods include flow cytometry and genetic tests, offering ...
SECAUCUS, N.J., Feb. 2, 2026 /PRNewswire/ --Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the launch of a novel blood test that uses advanced ...
clonoSEQ is the only DLBCL MRD assay available for clinical use and covered by Medicare SEATTLE, March 11, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial ...
Foundation Medicine, Inc., a global, patient-focused precision medicine company and an independent affiliate of Roche, announced it is set to expand its monitoring portfolio with SAGA Diagnostics' ...
FOSTER CITY, Calif., May 30, 2025 /PRNewswire/ -- Adela, Inc., an innovator in blood testing for molecular residual disease (MRD) monitoring and early cancer detection through a proprietary ...
MRD detection is the future — allowing us to monitor patients in real-time. The data is strong and we're excited that our approach can now be incorporated into future studies." Dr. Roy Herbst, study's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results